Tag Archives: ML6710i

Protected: Age-related Macular Degeneration (AMD)

There is no excerpt because this is a protected post.Age-related Macular Degeneration (AMD) AMD is a common eye condition among people aged 50 and older. It leads to the deterioration of the macula, the small central part of the retina responsible for sharp, central vision. Introduction to AMD AMD is a common eye condition and a leading cause of vision loss among people aged 50 and older. It causes damage to the macula, a small spot near the center of the retina, leading to central vision loss. Types of AMD Dry AMD Description: The Continue reading →

Novel ophthalmic laser system paired with focal electroretinography for subthreshold laser therapy of DME

Presented in: SPIE BIOS 2023 Authors: Jukka-Pekka Alanko, Eero Koivumäki, Laura Vesala, Johannes Kivelä, Zoe Ylöniemi, Petteri Uusimaa, Ossi Kaikkonen, Teemu Turunen, Jaakko Nieminen, Jani Tirronen    Presented in: SPIE BIOS 2023 Authors: Jukka-Pekka Alanko, Eero Koivumäki, Laura Vesala, Johannes Kivelä, Zoe Ylöniemi, Petteri Uusimaa, Ossi Kaikkonen, Teemu Turunen, Jaakko Nieminen, Jani Tirronen   In the field of ophthalmic treatments, subthreshold laser therapy (SLT) has shown promise in addressing retinal diseases like diabetic macular edema (DME) and age-related macular degeneration (AMD). However, the precise control of therapeutic temperatures is challenging due to variations in individual eye characteristics. Modulight and Maculaser have addressed this issue with their innovative ML6710i device. This device utilizes a combination of laser beams to achieve precise thermal Continue reading →

Novel ophthalmic PDT laser platform to target oncology and various other retinal indications

Presented in: SPIE BIOS 2023 Authors: Laura Vesala, Eero Koivumäki, Jukka-Pekka Alanko, Timo Tanila, Ivan Baldin, Zoe Ylöniemi, Petteri Uusimaa, Modulight Corp.    Presented in: SPIE BIOS 2023 Authors: Laura Vesala, Eero Koivumäki, Jukka-Pekka Alanko, Timo Tanila, Ivan Baldin, Zoe Ylöniemi, Petteri Uusimaa, Modulight Corp.   Laser systems, in ophthalmic applications, are utilized in the treatment of various ophthalmic diseases such as in ocular oncology and age-related macular degeneration through photochemical mechanism of photodynamic therapy. In addition, these lasers can be used to activate drug delivery systems in the retina to provide targeted drug therapy. PDT is a form of a combination treatment which utilizes light energy to Continue reading →

Ophthalmic laser platform utilizing AI to enhance treatment planning of liposomal drug release

Presented in: SPIE BIOS 2022 Authors: Eero Koivumäki, Laura Vesala, Jukka-Pekka Alanko, Timo Tanila, Petteri Uusimaa, Modulight Corporation (Finland)    Presented in: SPIE BIOS 2022 Authors: Eero Koivumäki, Laura Vesala, Jukka-Pekka Alanko, Timo Tanila, Petteri Uusimaa, Modulight Corporation (Finland)   Delivery of pharmaceuticals to the eye posterior poses a major challenge in ophthalmology. A promising drug delivery platform is indocyanine green (ICG) liposomes, which absorb near-infrared light resulting in a release of pharmaceutical molecules. The Modulight ophthalmic laser platform has been designed for treatments targeting the eye posterior and can also excite the absorption band of the liposomes. The laser connects with Modulight Cloud, enabling Continue reading →

Vision-sparing targeted phototherapy for uveal melanoma

Preliminary investigation of AU-011     Related Modulight products and Services   Related Publications Virus-Like Particle-Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Rhonda C. Kines, Cynthia D. Thompson, Sean Spring, Zhenyu Li, Elisabet de los Pinos, Stephen Monks and John T. Schiller Cancer Immunology Research, 2021, 9 (6)   A Phase 1b/2 Open-label Clinical Trial to Evaluate the Safety and Efficacy of AU-011 for the Treatment of Choroidal Melanoma Prithvi Mruthyunjaya, Amy C. Schefler, Ivana K. Continue reading →Customer case Aura Biosciences, headquartered in Cambridge, MA, is developing a new class of photoactivated therapy for cancer patients together with National Cancer Institute, Emory Eye Center and Wills Eye Hospital. The therapy is based on virus-like conjugates and its primary indication is uveal melanoma. The goal is to eventually develop this technology for multiple cancer indications, such as non-muscle invasive bladder cancer (NMIBC), for which plans are underway to conduct a clinical trial. Dr. Carol Shields, MD – Aura Biosciences Dr. Rhonda Kines, PhD – Continue reading →

New Insights on Management of CSCR

Retinal Physician – May 1, 2021  Currently, most retina specialists use photodynamic therapy (PDT) with verteporfin (Visudyne; Bausch + Lomb). Photodynamic therapy devices include ML6710i (available for investigational use only in the United States) by Modulight and ML7710 (CE certified; available for investigational use only in the United States) by Modulight.Retinal Physician - May 1, 2021  Currently, most retina specialists use photodynamic therapy (PDT) with verteporfin (Visudyne; Bausch + Lomb). Photodynamic therapy devices include ML6710i (available for investigational use only in the United States) by Modulight and ML7710 (CE certified; available for investigational use only in the United States) by Modulight. Read article

Modulight becomes exclusive supplier for BAUSCH + LOMB

BRIDGEWATER, N.J., December 04, 2018 – Bausch + Lomb, a leading global eye health company, and Modulight, Inc., a designer and manufacturer of lasers and optics for personalized medicine, announced the companies have entered into an exclusive agreement to collaborate and develop a new photodynamic laser specifically designed for use with Bausch + Lomb’s VISUDYNE® (verteporfin for injection) therapy. “Photodynamic therapy continues to be an important option for eye care professionals who treat choroidal neovascularization in patients who suffer from persistent disease activity, but the availability of lasers capable Continue reading →